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Abstract: The overall goal of this study was
to seek molecular linkages between
polyamines, casein kinase II, and the myc
oncoprotein by using a cell-free, highly
purified enzyme kinetic analysis. Casein
kinase II (CKII) was purified from sheep lung
tissue by using an original 3-column/3-day
set of procedures (DEAE cellulose, Sepharose
6L-4B, and poly-L- lysine agrose affinity
chromotographies). CKII was purified
approximately 550-fold with a recovery of
near 40% and a final specific activity of about
250,000 pmol of phosphorylated protein
substrate (casein)/min/mg of enzyme protein.
Kinetic evaluations with the purified CKII
using Mg-GTP as a phosphate donor, etiher
casein or myc oncoprotein as substrate, and
various polyamines (polylysine, polyornithine,

Introduction
Casein kinase II (CKII) is a ubiquitous enzyme which is
found in most cells and tissues of both prokaryotes and
eukaryotes (1-3). It is in low activity in differentiated cells
and in high activity in rapidly proliferating cells. Current
laboratory data support theories that CKII may play a
critical role in controlling cell proliferation by direct
involvement in both the signal transduction and cell cycle
control systems (4-5).
CKII phosphorylates more than 50 different proteins
including regulatory enzymes, structural proteins,
oncoproteins, and cancer suppressor genes’s proteins (57). It uses either ATP or GTP, and magnesium or
manganese as phosphate donor substrates. Several of the
substrate proteins of CKII, such as myc oncoprotein and
p53 cancer suppessor protein, are directly involved in the
control of both cell proliferation and the cell cycle (8-10).
In addition, CKII is activated by various natural and

spermidine, or spermine) as stimulators
showed: 1) phosphorylation of casein
icreased 2-4 fold with various polyamines; 2)
without polyamines, phosphorylation of myc
oncoprotein was about 10-20% when
compared to casein; 3) phosphorylation of
myc oncoprotein increased 10- to 30-fold in
the presence of various polyamines. The
phosphorylated form of myc oncoprotein is
the only biologically active form which
transactivates specific genes related to cell
proliferation.

Key Words: Casein kinase II, polyamines,
myc, cell proliferation abbreviations: CKIIcasein kinase II; Pmyc-phosphorylated myc
oncoprotein; Pmax-phosphorylated max
protein.

synthetic polyamines (11-14). The natural polyamines,
spermidine and spermine, increase in all mammalian cells
which undergo rapid cell proliferation (15-16). Various
drugs have been developed which inhibit polyamine
synthesis or polyamine function, thus inhibiting cell
proliferation (17-19). Combinations of these two types
of polyamine inhibitors are currently being evaluated in
laboratory and clinical cancer studies (16-19).
Therefore, molecular linkages may exist, especially in
rapidly growing cells, between polyamines, CKII, and
certain CKII protein substrates such as the protein
product of the myc oncogene. The phosphorylated myc
oncoprotein is involved in events in the cell cycle, cell
proliferation and differentiation, and apoptosis (20-23).
The current report describes an original, very rapid and
efficient purification of CKII from normal sheep lung and
the phosphorylation of the myc protein as a substrate in
the absence or presence of various polyamines.

* This study was partially supported by TÜBITAK grant TAG no 0776 and DPT grand no 95K-120-410.
** For repint requests please write to Prof.Dr. Wayne E Criss. page heading title: Lung CKII, Polymanies, and myc Oncoprotein.
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Materials and Methods
Most of the general chemicals and biologicals were
purchased from commercial sources. Purification was
performed using fresh sheep lung tissue. The tissue was
minced and homogenized (1gm/3ml) in ice-cold buffer
containing o.1M Tris-HCl (pH 7.5), 2mM EDTA, and
2mM mercaptoethanol (Buffer A). All purification
procedures were carried out at 3-5˚C. The homogenate
was centrifuged a 40,000Xg for 2 hours. The
supernatant (cytosol) was used for the subsequent
purification of CKII.
120ml of the cytosol was applied to a 2.5cm X 26cm
DEAE cellulose column which was pre-equilibrated with a
buffer containing 10mM TRIS-HCL (pH 7.5), 2mM
EDTA, and 2mM mercaptoethanol (Buffer B). The column
was washed continously with Buffer B (2-3 column
volumes) until the elutant was free of hemoglobin. The
flow rate was then adjusted to 100ml/hr and proteins
were eluted using 6ml batches of Buffer B containing
NaCl from 0.1 to 1.0M (discontinuous gradient elution).
All fractions were assayed for CKII activity as described
below.
The CKII activity was assayed by measuring
radioactive phopshate from gamma 32P-GTP that was
incorporated into acid precipitable proteins after the
addition of protein substrates (24-25). Casein was used
as substrate during the purification procedures, while
casein or myc oncoprotein was used during the kinetic
evaluations. The assay cocktail contained 20mM TRIS-HCl
buffer (pH7.5), 10mM magnesium acetate, 80µM EDTA,
80µM mercaptoethanol, 0.2µM of gamma 32P-GTP
(5000Ci/mmol) in 10µM of nonradioactive GTP. Each
assay contained approximately 200,000cpm, 10µg of
casein, 10µg of myc protein, and/or 10µg of poly-Llysine. All assays were performed in 1.5ml microfuge
tubes for 10min at 37˚C in a water bath. The final assay
volume was 250µl. The reaction was stopped by the
addition of 1ml of ice-cold 10% TCA and placing the
microfuge tube into ice water. Acid precipitable materials
were collected by centrifuging the microfuge tube at
12,000Xg for 15min at 4˚C. The precipitate was washed
twice with 1ml of the cold 10% TCA. The washed
precipate was dissolved in 0.5ml of 1N NaOH at room
temperature. It was then added into 5ml of a scintillation
cocktail containing 1% PPO, 0.025% POPOP, and 20%
naphtaline in 1,4 dioxane and counted in the liquid
scintillation counter.
Fractions containing CKII activity were pooled and
concentrated 5-10-fold using a nucleopore concentrator
with Diaflo ultrafilter YM 100 membranes. The

600

concentrated CKII activity was mounted onto a 1.5cm x
110cm glass column containing Sepharose CL-6B which
was equilibrated with Buffer B. The column was washed
with Buffer B at a flow rate of 5ml/hr. Fractions were
collected and assayed for CKII activity as previously
described. Fractions containing CKII activity were pooled
and concentrated 5- to 10-fold as previously described.
The concentrated CKII activity was then mounted onto
1.2cm x 5cm glass column containing poly-L-lysine
agarose equilibrated with Buffer B. The column was
washed with several volumes of Buffer B. Proteins were
then eluted using 5ml batches of Buffer B containing NaCl
from 0.1 to 1.0M. Five ml fractions were collected and
assayed for CKII activity. Fractions containing CKII
activity were pooled, concentrated, and ultrafiltration
dialized to remove NaCl. The sheep lung CKII as purified
by this 3-column/3-day procedure was used for all
subsequent kinetic studies
Results
CKII activity was released from the DEAE column with
0.15M NaCl in Buffer B (Figure 1). Elution from the
Sepharose 6L-4B column occured near the void volume
using Buffer B, which indicated that CKII had an
aggregated molecular weight near several million daltons
at this stage in the purification scheme (Figure 2). CKII
bound very tightly to the poly-L-lysine affinity agrose
column and eluted using 0.9M NaCl in Buffer B (Figure
3). After concentration and ultrafiltration dialysis, this
original 3-column/3-day set of proceedures yielded a CKII
enyzme preparation which was purified approximately
550-fold, gave a recovery of near 40%, and had a final
specific activity of about 250,000 pmole of
phosphorylated casein per min per mg of enzyme protein
(Table 1). In addition, the purified lung CKII used MgATP
as phosphate donor equally as well as it did MgGTP (data
not given).
The kinetic evaluations of the purified CKII with
casein, myc oncoprotein, and various polyamines are
given in Table 2. Without added protein substrate,
miminal phosphorylation (350+19) always occurred.
Addition of polylysine in the absence of added protein
substrate also allowed minimal (500+38) enzymatic
activity. These observations are probably a result of
enzyme self phosphorylation (14). With casein added as
protein substrate, enzyme activity was high (2356+109)
and increased 2-4 fold in the presence of polylysine,
polyornithine, spermidine, and spermine (8021-310,
7346+356, 3901+196, and 4033+209), respectively.
With myc oncoprotein added as protein substrate,
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Purification

Volume
Steps

PURIFICATION OF LUNG CASEIN KINASE II
Protein
Enzyme
Units
Recovery
(ml)
(mg)
Units*
/mg

Table 1.
Purification
(%)

(fold)
(x1000)

cytosol

120

480

704

1,468

100

0

DEAE
Cellulose
Column

70

74.6

1615

21,765

229

14.6

40

24.8

1127

45,448

160

30.9

20

0.36

289

802,778

41

546.8

Sepharose
Column
Polylysine
Aff`nity
Column

*Unuts-dpm 32P/min assay
Final Specific Activity-near 2500,000 pmole of phosphorylated substrate protein (casein) per
min per mg enzyme protein.

NaCl (M)
0.2

0.4

0.6

0.8

oncoprotein are about 7700 and 8500, respectively.
Therefore, polylysine stimulation of myc oncoprotein
phosphorylation could be as high 30 fold under these
assay conditions.

1.0

15

1.5

Discussion
1.0
A280

dpm x 1000

11

7

0.5

3

10

20

30

40

50

60

Fraction No.
Figure 1.

Elution Pattern for CKII from the DEAE-Cellulose Column;
triangles-CKII activity; circles-optical absorbancy at
280nm.

enzymatic activity was low (621+55); however, it
increased 5- to 15-fold in the presence of polylysine,
polyornithine, spermidine, and spermine (8879+426,
7911+374, 3067+178, and 3711+224), respectively.
And if one considers that the only-polylysine (no substrate
added) assay represents CKII self phosphorylation (3, 6,
14), then the true non-stimulated CKII phosphorylation
of casein and myc oncoprotein are approximately 2000
and 300, respectively. Using this assumption, polylysine
stimulated phosphorylation of casein and myc

Homogenization of lung tissue in 0.1M Tris-HCl and
mounting of the cytosol onto a DEAE cellulose column
equilibrated with 10mM Tris-HCl prevents many protein
kinases from binding, but the disaggregated form of CKII
binds very efficiently. This proceedure accomplished
several critical objectives: it partially separates CKII from
its naturally bound substrates, and it allows the enzyme
to disaggregate into its minimal 4 subunit state (2 alpha
and 2 beta peptides, totalling 140,000 daltons). In a NaCl
free/low-ionic-strength buffer, CKII exists in a range of
aggregated forms of several million daltons. These
aggregated forms bind to and detach from DEAE with
varying degrees of affinity. Under these conditions many
other protein kinases do not bind, including the cyclic
nucleotide dependent protein kinases. There fore, this
procedure allows for a more efficient binding and release
of CKII on DEAE cellulose, removal of substrates and
inhibitors which are endogenously bound to CKII, and a
more accurate assay of ‘native’ CKII activity after elution
from the DEAE column (11-17, 24-26).
In addition, the binding of CKII to a polylysine affinity
resin in NaCl-free media and subsequent release at 0.9M
NaCl allowed for a 20-fold increase in purification, but

601

Pirification of Casein Kinase II From Lung Tissue and Kinetic Evaluations With Polyamines and Myc-Oncoprotein

Table 2.

KINETIC STUDIES WITH PURIFIED LUNG CASEIN KINASE II
Enzyme Activity*
Using casein as substrate
– CKII only (no subtrate added)
350±019
– CKII+casein
2356±109
– CKII+polylysine (no substrate added)
500±038
– CKII+casein+polylysine
8021±310
– CKII+casein+polyornithine
7346±356
– CKII+casein+spermidine
3901±196
– CKII+casein+spermine
4033±209
Using myc protein as substrate
– CKII only (no substrate added)
, CKII+myc
– CKII+polylysine (no substrate added)
– CKII+polylysine (no substrate added)
– CKII+myc+polylysine
– CKII+myc+polyornithine
– CKII+myc+spermidine
– CKII+myc+spermine

335±021
621±055
423±047
423±047
8897±426
7911±374
3067±178
3711±224

* Enzyme Activity is given as dpm 32P±standard error/10 min assay of 4-6 determinations.
casein-10µg; myc protein-10µg; polylysine-10µg; polyornithine-10µg; spermidine-50µg;
spermine-50µg.
NaCl (M)

20
0.2

0.6

0.8

1.0

16

15
1.0

12

0.5
5

10

20

30

40

2.0
A280

10

dpm x 1000

A280

dpm x 1000

0.4

8

1.0
4

50

Fraction No.
2
Figure 2.

Elution Pattern for CKII from the Sepharose 6L-4B Column;
triangles-CKII activity; circles-optical absorbancy at
280nm.

caused a 70% loss in total CKII activity from the previous
purification step. Such a procedure has never been
reported for CKII and suggests that various polymer
forms of CKII may have different binding affinities to
polyamines. This original 3-day/3-column set of
purification procedures is the fastest and most efficient
ever reported for CKII.
All types of fast growing normal and cancer tissues
have extremely high levels of ornithine decarboxylase
(ODC), polyamines, CKII activity, and myc oncoprotein (7,
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4

6

8

1.0

Fraction No.
Figure 3.

Elution Pattern for CKII from the Poly-L-lysine Agarose
Affinity Column; triangles-CKII activity; circles-optical
absorbancy at 280nm.

9-10, 16, 22-23). Linkages between these molecular
systems are being evaluated by many labs. Our current
enzyme kinetics report evaluates a highly purified CKII,
using myc oncoprotein as substrate, in the absence and
presence of various polymanies. The data suggests that
myc oncoprotein is a very poor substrate unless
polylamines are present.
The myc oncoprotein can be phosphorylated on 4 or
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5 serine/threonine residues by different protein kinases.
Non-phosphorylated myc oncoprotein is not biologically
active. Phosphorylation of myc oncoprotein (Pmyc) is
necessary to allow a heterodimerization to a
phosphorylated max protein (Pmax), the latter of which
is usually present in abundance in most mammalian cells.
The Pmyc-Pmax system is described below (27-31).
1)

max-max homodiers have no activity

2) Pmax-Pmax homodimers bind to the DNA
binding domain of CAGTG and inhibit gene transcription
3)

myc-myc homodimers do not exist

4) Pmyc-Pmyc homodimers occur but have little
activity
5) Pmyc-Pmax heterodimers bind tightly to the
DNA binding domain of CACGTG and stimulate gene
transcription.
In most fast growing cancers, amphlification of the
myc oncogene occurs either by chromosomal
nondisjunction (allows for multiple copies of myc
oncogene), or by mutation in a complex control region of
the gene immediately before exon 1 (allows for increased
transcription of the gene). Both types of amphlification
mechanisms result in increased quantities of a normal
myc oncoprotein, not a mutated protein. However, the
myc oncoprotein (and the max protein) are not
biologically active until after several protein kinase

phosphorylations. Pmyc-Pmax is the only form which
transactivates genes. It is currently not understood which
protein kinase phosphorylates which serine/threonine
residue, nor which phosphorylation allows biological
activity. Because some protein kinases are cytoplasmic
rather than nuclear, and because proteins usually gain
nuclear entry only after being phosphorylated, certain
phosphorylations on the myc oncoprotein may be related
to nuclear entry and others to heterodimerization or DNA
binding. Many oncoproteins and cancer suppressor
proteins require phosophorylation to become biologically
active molecules. However, further studies are necessary
to clarify the effects that CKII phosphorylations have on
myc oncoprotein functioning.
In summary, we have developed a new 3-step/3-day
set of procedures to purify CKII from lung tissue. We
used this highly purified enzyme to kinetically determine
that myc oncoprotein phosphorylation by CKII is very low
in the absence of polyamines but is increased 10- to 30fold in the presence of polyamines. Only the
phosphorylated form of myc oncoprotein (as a PmycPmax heterodimer) can transactivate genes such as the
ODC gene, the rate-limiting enzyme for polyamine
systhesis. Such potential linkages are critical in our
attemps to understand the molecular mechanisms of cell
proliferation (32-38).
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